Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
